Loading…
Loading…
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Is BBH's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.
Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to the 25 positions in VanEck Biotech ETF VanEck Biotech ETF has a slightly lower expense ratio of 0.35% while Invesco S&P 500 Equal Weight Health Care ETF charges 0.40% Invesco S&P 500 Equal Weight Health Care ETF has experienced a significantly lower five-year maximum drawdown than the biotech fund
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.
iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries significantly greater historical price volatility iShares U.S. Healthcare ETF offers a higher dividend yield and lower five-year maximum drawdown for income-focused investors
State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost 40% over the last five years.